Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BOrient Pharma Co., Ltd. 〉ORADUR-methylphenidate

ORADUR-methylphenidate

ORADUR-methylphenidate

1. Anti-deterrent (drug abuse) property2. Smaller capsule is suitable for children3. Better Pharmacokinetic profile

Request for Collaboration
Overview
  1. Tmax of the current extended release tablets is too long, so children lose attention in learning when they start classes in the early morning.
  2. With both advantages of immediate and extended release, the unique multi-stages hot melt capsule releasing technology is able to become effective in early stage and sustainably release the drug to maintain the efficacy.
  3. The patented Oradur®  formulation is extremely hard to be dissolved by water and alcohol to avoid the drug abuse.
Application
Attention Deficit Hyperactivity Disorder (ADHD)
Collaboration Options
Open for collaboration
People who like this also like
  • Chemistry Manufacturing and Controls (CMC)Chemistry Manufacturing and Controls (CMC)
  • JHL1255 Ustekinumab BiosimilarJHL1255 Ustekinumab Biosimilar
  • Multi-day Transdermal Drug Delivery (MTDD)Multi-day Transdermal Drug Delivery (MTDD)
  • Complete and Comprehensive Design/Production CapabilitiesComplete and Comprehensive Design/Production Capabilities
  • Taigexyn®  (Nemonoxacin)Taigexyn® (Nemonoxacin)
  • Newborn genetic screening for hearing impairment using real-time PCR with FRET probesNewborn genetic screening for hearing impairment using real-time PCR with FRET probes
  • Clinical & Regulatory ExpertiseClinical & Regulatory Expertise
  • Cell selection adhesion technologyCell selection adhesion technology
  • Platform_NanoX™Platform_NanoX™
  • Cast-MoldingCast-Molding